Founded by the top-notch biologist Dr. Yi Rao in 2019, Gritgen is dedicated to make "Great Science for human health" and committed to becoming a global biotech by innovative research.
Platform and Pipeline
Adeno associated virus (AAV), not readily to cause an immune reaction and integrated into the genome of the target cell, is a safe and broadly applicable vector for gene therapy. The gene, capsid, promotor and enhancer are the key components of a vector. We developed propriatary, next-generation AAV capsid platform and high effient promotor and enhancer system. Combining with the fundamental understanding of the genetics and underlying biology of diseases, Gritgen has developed a robust pipeline spanning from rare diseases to common diseases.